Thomas Aaberg, MD
Retina Specialist · Grand Rapids, MINPI 1194753186
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,938 of the $25,120 with a category attached, or 63.4%. Regeneron Healthcare Solutions, Inc. accounts for 60.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $5,901 and has fallen 74.7% since, to $1,494 in 2025.
Across 140 payments — averaging $179.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$15K
- Alimera Sciences, Inc.$3K
- US Retina LLC$2K
- Sanofi$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- AbbVie$741
- plus $2K from 22 others
Across 88 payments — averaging $6420.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$272K
- Eyepoint US, Inc.$222K
- Genentech, Inc.$72K
What the payments were for
- Consulting fees$15,93863%
- Travel & lodging$1,0734%
- Food & beverage$5,75823%
- Ownership interest$2,3529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 24 | $15,143 |
| Alimera Sciences, Inc. | 13 | $2,544 |
| US Retina LLC | 5 | $2,352 |
| Sanofi | 1 | $1,280 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $1,178 |
| AbbVie(2 entities) | 31 | $741 |
| Genentech USA, Inc. | 10 | $312 |
| Alcon | 5 | $239 |
| Coherus Oncology, Inc. | 2 | $168 |
| Amgen(2 entities) | 3 | $166 |
| Astellas Pharma US Inc | 4 | $150 |
| Regeneron | 1 | $118 |
| Eyepoint US, Inc. | 6 | $117 |
| Novartis | 6 | $100 |
| ANI Pharmaceuticals, Inc. | 3 | $90 |
| Hoffmann-la Roche Limited | 1 | $64 |
| Sandoz | 2 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Biogen | 2 | $40 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 2 | $33 |
| Biotissue Holdings Inc. | 2 | $31 |
| Spark Therapeutics, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Genentech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,120 in reported general payments places this provider in the 80th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 12 | $4,087 |
| Prednisolone Acetate | 59 | $3,123 |
| Difluprednate | 25 | $2,694 |
| Timolol Maleate | 57 | $772 |
| MethotrexateMethotrexate Sodium | 17 | $685 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $614 |
| Latanoprost | 18 | $479 |
| Brimonidine Tartrate | 18 | $376 |
| Dorzolamide Hcl | 14 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,178 | $4,08712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 retina specialist providers in Michigan.
Other retina specialist in Grand Rapids
- Edward KorotGrand Rapids$44K
- Liliya SutherlandGrand Rapids$13K
- Nathan PezdaGrand Rapids$13K
- Greg BeverGrand Rapids$4K
- Alan MargherioGrand Rapids$0
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Asheesh TewariDearborn$204K
- Sandeep RandhawaRoyal Oak$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.